Today: 11 June 2026
Pentagon-Lockheed deal aims to triple PAC-3 Patriot interceptor output to 2,000 a year
7 January 2026
2 mins read

Pentagon-Lockheed deal aims to triple PAC-3 Patriot interceptor output to 2,000 a year

PentagoWASHINGTON, January 7, 2026, 15:34 (EST)

The U.S. Department of War said it has signed a seven-year framework agreement with Lockheed Martin to lift annual production of the PAC-3 Missile Segment Enhancement (MSE) — a Patriot interceptor meant to hit incoming missiles — to about 2,000 units from roughly 600. The department said it will also work with key suppliers on seven-year subcontracts, part of what it calls a new acquisition model. Michael Duffey, the under secretary for acquisition and sustainment, called it “a fundamental shift in how we rapidly expand munitions production.” U.S. Department of War

Demand for Patriot interceptors has climbed as the United States and allied countries push harder on air defenses amid broader geopolitical tensions. Lockheed supplies PAC-3 to the United States and 16 other countries, including Sweden, Qatar, Japan and Poland, and the Patriot system is among the weapons the West has sent to Ukraine, the company said. In September 2025, Lockheed was awarded a $9.8 billion contract for 1,970 Patriot missiles, the largest order ever placed for the weapon, it added.

The PAC-3 is engineered to strike and destroy inbound threats, including tactical ballistic missiles and cruise missiles. The MSE variant uses a two-pulse rocket motor that extends its reach to higher altitudes and longer ranges, industry reporting showed. The production push comes as the Pentagon works on what it has described as a “Golden Dome” missile defense effort and as partners seek more air-defense interceptors. Defense News

Lockheed said the framework is meant to give industry longer demand signals and a financing approach aimed at keeping early cash flows roughly neutral as suppliers invest. Chief executive Jim Taiclet said the deal should create “unprecedented capacity for PAC-3 MSE production.” Lockheed said it expects an initial contract award in final fiscal 2026 congressional appropriations. Media – Lockheed Martin

Taiclet has said Lockheed is aiming for the 2,000-a-year rate by the end of 2030, leaning on existing factory floor space while adding workers, tools and automation. The draft structure includes inflation provisions and reimbursement for certain one-off engineering costs — essentially the up-front design and tooling bill — if Congress or the Pentagon shortens the agreement, but the first award still depends on lawmakers signing off on the funding. Tom Karako, a missile defense analyst at the Center for Strategic and International Studies, said, “The demand signal is massive,” but warned the ramp likely reflects hard limits in supply chains as much as need. Breaking Defense

The PAC-3 is one of several interceptor types used in the Patriot air and missile defense system, which RTX’s Raytheon markets globally. Raytheon says Patriot ties together radars and command-and-control with multiple interceptor options, and it pitches the system as a core air-defense layer for 19 nations.

The agreement also lands in a harsher political climate for big defense contractors. President Donald Trump said on Wednesday he would block dividends and share buybacks by defense firms until they speed up weapons production, but did not spell out how he would enforce it.

For Lockheed and its suppliers, the bet is steadier orders in exchange for bigger up-front investments that are hard to justify on one-year contracts. For the Pentagon, it is a wager that predictability buys speed — and that the money holds together when the first binding awards hit Capitol Hill.

Stock Market Today

  • Live Cattle Futures Edge Higher Amid Mixed USDA Beef Prices
    June 11, 2026, 10:54 AM EDT. Live cattle futures rose by $1.45 to $1.60 across most front months on Wednesday, with December delivery slightly down. Feeder cattle futures gained $2.40 to $2.90 by midday. Open interest increased by 1,293 contracts. Managed money trimmed net long positions in live cattle futures and options by 7,083 contracts, totaling 101,265, while feeder cattle spec funds reduced holdings by 470 contracts. USDA reported a decline in wholesale boxed beef prices, with Choice boxes down $1.68 to $359.36 and Select down $3.15 to $344.88. Federally inspected cattle slaughter rose to an estimated 123,000 head Wednesday, exceeding last week but falling short of last year. The mixed data signals ongoing volatility in cattle markets as traders assess supply and demand factors.

Latest articles

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

11 June 2026
TOVX soared 74.6% to $0.4252 after Theriva Biologics published Phase 1 VCN-01 data showing survival and biomarker signals in head-and-neck cancer, but the jump was not due to drug approval or revenue; investors face ongoing financing, dilution, and clinical-trial execution risks, with the company’s cash runway only into Q1 2027 and substantial doubt about its ability to continue as a going concern without new capital.
Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

11 June 2026
Trulieve began NYSE trading as TRLV this week after moving from OTC/CSE, authorized a buyback of up to $50 million or 8.5 million shares, and closed its first NYSE session at $11.50, down 0.43%, before trading near $11.78 early Thursday, as investors weigh whether the uplisting and buyback will boost demand amid ongoing federal cannabis policy uncertainty.
Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

11 June 2026
Propanc Biopharma shares soared as much as 392% after authorizing up to $5 million in stock buybacks—exceeding its prior $3.1 million equity value—even as it reported just $443,702 in cash and flagged going-concern risks, with investors now focused on whether its lead cancer drug PRP will advance to a planned Phase 1b trial this year.
Europa Clipper’s UV look at Comet 3I/ATLAS backs water-ice call as radio “technosignature” scan finds none
Previous Story

Europa Clipper’s UV look at Comet 3I/ATLAS backs water-ice call as radio “technosignature” scan finds none

AMD stock slips after hours as CES AI chip blitz sets up Feb. 3 earnings test
Next Story

AMD stock slips after hours as CES AI chip blitz sets up Feb. 3 earnings test

Go toTop